Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial

Clinical Gastroenterology and Hepatology

Volumn 3, Issue 8, 2005, Pages 761-771

  Arnold, Rudolf ^a   Rinke, Anja ^a   Klose, Klaus Jochen ^a   Müller, Hans Helge ^a   Wied, Matthias ^a   Zamzow, Karin ^a   Schmidt, Christina ^a   Schade Brittinger, Carmen ^a   Barth, Peter ^a   Moll, Roland ^a   Koller, Michael ^a   Unterhalt, Michael ^b   Hiddemann, Wolfgang ^b   Schmidt Lauber, Martin ^c   Pavel, Marianne ^d   Arnold, Christian N ^e  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Civic Hospital   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; KI 67 ANTIGEN; OCTREOTIDE; RECOMBINANT ALPHA2A INTERFERON;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ENDOCRINE TUMOR; FEMALE; FEVER; GASTROINTESTINAL TUMOR; HEART ARRHYTHMIA; HUMAN; INTERMETHOD COMPARISON; LEUKOCYTE DISORDER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR GROWTH; TUMOR REGRESSION; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMOGRANIN A; CHROMOGRANINS; FEMALE; GERMANY; HUMANS; HYDROXYINDOLEACETIC ACID; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; INTESTINAL NEOPLASMS; KI-67 ANTIGEN; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATIC NEOPLASMS; QUALITY OF LIFE;

EID: 23644436501     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(05)00481-7     Document Type: Article

References (55)

1. R. Arnold, B. Simon, M. Wied Treatment of neuroendocrine GEP tumours with somatostatin analogues Digestion 62 Suppl 1 2000 84 91
2. J.D. Godwin Carcinoid tumors an analysis of 2837 cases Cancer 36 1975 560 569
3. E.D. Williams, M. Sandler The classification of carcinoid tumors Lancet 75 1963 140 146
4. I.M. Modlin, K.D. Lye, M. Kidd A 5-decade analysis of 13,715 carcinoid tumors Cancer 97 2003 934 959
5. G. Rindi, C. Bordi, S. Rappel Gastric carcinoids and neuroendocrine carcinomas pathogenesis, pathology, and behavior World J Surg 20 1996 168 172
6. J. Lowney, G.M. Doherty Surgery of endocrine tumors of the pancreas G.M. Doherty B. Skogseid Surgical endocrinology 2001 Lippincott Williams & Wilkins Philadelphia 381 392
7. G. Akerström, P. Hellman, U. Öhrvall Midgut and hindgut carcinoid tumors G.M. Doherty B. Skögseid Surgical endocrinology 2001 Lippincott Williams & Wilkins Philadelphia 447 459
8. H. Chen, J.M. Hardacre, A. Uzar Isolated liver metastases from neuroendocrine tumors does resection prolong survival? J Am Coll Surg 187 1998 88 92
9. H. Nave, E. Mössinger, H. Feist Surgery as primary treatment in patients with liver metastases from carcinoid tumors a retrospective, unicentric study over 13 years Surgery 129 2001 170 175
10. R.S. Chamberlain, D. Canes, K.T. Brown Hepatic neuroendocrine metastases does intervention alter outcomes? J Am Coll Surg 190 2000 432 445
11. D. Jaeck, E. Oussoultzoglou, P. Bachellier Hepatic metastases of gastroenteropancreatic neuroendocrine tumors safe hepatic surgery World J Surg 25 2001 689 692
12. J.M. Sarmiento, G. Heywood, J. Rubin Surgical treatment of neuroendocrine metastases to the liver a plea for resection to increase survival J Am Coll Surg 197 2003 29 37
13. P. Ruszniewski, P. Rougier, A. Roche Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors Cancer 71 1993 2624 2630
14. O. Kress, J.H. Wagner, M. Wied Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors a retrospective single-center analysis Digestion 68 2003 94 101
15. A. Otte, R. Herrmann, A. Heppeler Yttrium-90 DOTATOC first clinical results Eur J Nucl Med 26 1999 1439 1447
16. 3]octreotide, a promising somatostatin analogue for radionuclide therapy Eur J Nucl Med 24 1997 368 371
17. 90-Y-DOTATOC) in the treatment of neuroendocrine tumours a clinical Phase II study Ann Oncol 12 2001 941 945
18. C.G. Moertel, M. Lefkopoulo, S. Lipsitz Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma N Engl J Med 326 1992 519 523
19. B. Dousset, O. Saint-Marc, J. Pitre Metastatic endocrine tumors medical treatment, surgical resection, or liver transplantation World J Surg 20 1996 908 915
20. M. Anthuber, K.W. Jauch, J. Briegel Results of liver transplantation from gastroenteropancreatic tumor metastases World J Surg 20 1996 73 76
21. C. Makridis, A. Ekbom, J. Bring Survival and daily physical activity in patients treated for advanced mitgut carcinoid tumors Surgery 122 1997 1075 1082
22. J.J. Shepherd, G.B. Senator Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995 Lancet ii 1986 574
23. B. Wiedenmann, U. Rath, R. Rädsch Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995 Klin Wochenschrift 66 1988 75 77
24. M.E. Kraenzlin, J.C. Ch'ng, S.M. Wood Can inhibition of hormone secretion be associated with endocrine tumour shrinkage? Lancet II 1983 1501 1504
25. D. Clements, E. Elias Regression of metastatic VIPoma with somatostatin analogue SMS 201-995 Lancet I 1985 874 875
26. K.E. Imtiaz, P. Monteith, A. Khaleeli complete histological regression of metastatic carcinoid tumour treatment with octreotide Clin Endocrinol 53 2000 755 758
27. L. Saltz, B. Trochanowski, M. Buckley Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumours Cancer 72 1993 244 248
28. M. Di Bartolomeo, E. Bajetta, R. Buzzoni Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumours Cancer 77 1996 402 408
29. M. Ducreux, P.H. Ruszniewski, J.A. Chayvialle The antitumoural effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumours Am J Gastroenterol 95 2000 3276 3281
30. S. Faiss, U. Rath, U. Mansmann Ultrahigh dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumours Digestion 60 1999 469 476
31. B. Eriksson, J. Renstrup, H. Iman High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumours clinical and biological effects Ann Oncol 8 1997 1041 1044
32. R. Arnold, M. Wied, T.H. Behr Somatostatin analogues in the treatment of endocrine tumours of the gastrointestinal tract Expert Opin Pharmacother 3 2002 643 656
33. K. Oberg, B. Eriksson The role of interferons in the management of carcinoid tumours Br J Haematol 79 Suppl 1 1991 74 77
34. K. Oberg, B. Eriksson, E.T. Janson Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors Digestion 55 Suppl 3 1994 64 69
35. H. Joensun, K. Katka, H. Kujari Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide Acta Endocrinologica (Copenhagen) 126 1992 184 185
36. E.T. Janson, K. Oberg Long-term management of the carcinoid syndrome treatment with octreotide alone and in combination with alpha-interferon Acta Oncologica 32 1993 225 229
37. M. Frank, K.J. Klose, M. Wied Combination therapy with octreotide and α-interferon effect of tumour growth in metastatic endocrine gastroenteropancreatic tumours Am J Gastroenterol 94 1999 1382 1387
38. R. Arnold, M.E. Trautmann, W. Creutzfeldt Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours Gut 38 1996 430 438
39. J.K. Ramage Quality of life issues identified by healthcare workers and patients with metastatic carcinoid/neuroendocrine tumours C.D. Johnson C.W. Imrie Pancreatic disease basic science and clinical management 2004 Springer New York
40. N.K. Aaronson, S. Ahmedzai, B. Bergman The European organization for research and treatment of cancer QLQ-C30 a quality of life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
41. P. Fayers, N.K. Aaronson, K. Bjordal EORTC QLQ-C30 scoring manual 3rd ed 2001 EORTC Study Group on Quality of Life Brussels
42. M. Mengel, R. von Wasielewski, B. Wiese Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial J Pathol 198 2002 292 299
43. V. Kuenen-Boumeester, A.M. Timmermans, E.M. De Bruijn Immunocytochemical detection of prognostic markers in breast cancer; technical considerations Cytopathology 10 1999 308 316
44. K.K.G. Lan, D.L. DeMets Discrete sequential boundaries for clinical trials Biometrika 70 1983 659 663
45. D.A. Schoenfeld, J.R. Richter Normograms for calculating the number of patients needed for a clinical trial with survival as an endpoint Biometrics 38 1982 163 170
46. H. Schäfer, H.H. Müller Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections Stat Med 20 2001 3741 3751
47. S. Faiss, U.R. Pape, M. Bohmig the international lanreotide and interferon alfa study group Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and combination on gastroenteropancreatic tumors J Clin Oncol 21 2003 2689 2696
48. M. Ducreux, P. Ruszniewski, J.A. Chayvialle The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors Am J Gastroenterol 95 2000 3276 3281
49. T. Aparicio, M. Ducreux, E. Baudin Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours Eur J Cancer 37 2001 1014 1019
50. H. Shojamanesh, F. Gibril, A. Louie Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma Cancer 94 2002 331 343
51. S. Ricci, A. Antonuzzo, L. Galli Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide Ann Oncol 11 2000 1127 1130
52. S. Ricci, A. Antonuzzo, L. Galli Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors Am J Clin Oncol 23 2000 412 415
53. G. Rindi, C. Azzoni, S. La Rosa ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach prognostic evaluation by pathological analysis Gastroenterology 116 1999 532 542
54. S. La Rosa, F. Sessa, C. Capella Prognostic criteria in nonfunctioning pancreatic endocrine tumors Virchows Arch 429 1996 323 333
55. J. Garland, J.R. Buscombe, C. Bouvier Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome a 3-year experience Aliment Pharmacol Ther 17 2003 437 444